Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.75 |
| ▸ | BCR | P11274 | 13/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.75 |
| ▸ | SRC | P12931 | 3/20 | 0.75 |
| ▸ | SYK | P43405 | 2/20 | 0.75 |
| ▸ | KIT | P10721 | 10/20 | 0.65 |
| ▸ | ABL2 | P42684 | 5/20 | 0.65 |
| ▸ | EGFR | P00533 | 3/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.65 |
| ▸ | LCK | P06239 | 2/20 | 0.65 |
| ▸ | FYN | P06241 | 2/20 | 0.65 |
| ▸ | CSF1R | P07333 | 2/20 | 0.65 |
| ▸ | LYN | P07948 | 2/20 | 0.65 |
| ▸ | FGR | P09769 | 2/20 | 0.65 |
| ▸ | BRAF | P15056 | 2/20 | 0.65 |
| ▸ | NQO2 | P16083 | 2/20 | 0.65 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.65 |
| ▸ | FRK | P42685 | 2/20 | 0.65 |
| ▸ | BLK | P51451 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191704 | 0.88 | ABL1 (0.72) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL9485 | 0.85 | ABL1 (1.00) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL3866664 | 0.83 | ABL1 (0.94) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL8261009 | 0.83 | ABL1 (0.94) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL23258781 | 0.82 | ABL1 (0.71) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL2317952 | 0.82 | ABL1 (0.70) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL10075315 | 0.82 | ABL1 (0.70) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL27810491 | 0.82 | ABL1 (0.78) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL10109122 | 0.81 | ABL1 (0.72) | ABL1BCRPDGFRAPDGFRBSRC | |
| SCHEMBL4902292 | 0.81 | ABL1 (0.86) | ABL1BCRPDGFRAPDGFRBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116381-A1 | 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases | FAGIN JAMES A | 2006-06-01 | — | — | US | disclosed |
| US-20060111363-A1 | Treatment of uveal melanoma | ALL-ERICSSON CHARLOTTA | 2006-05-25 | — | — | US | disclosed |
| US-6894051-B1 | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | NOVARTIS AG (CH) | 2005-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111363-A1 | Treatment of uveal melanoma | MITF, ALDH1A2, UACA | ABL1 2500/4885BCR 4868/4885PDGFRA 2945/4885 |
| US-20060116381-A1 | 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases | RET, MECP2, GRK4 | ABL1 130/4885BCR 575/4885PDGFRA 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.